Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 8,157 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects

NCT01260155
View directory record Official record
Conditions
Healthy Subjects
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 28, 2026, 9:42 PM EDT
Terminated Phase 4 Interventional Results available

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

NCT00430716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05633355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Phoenix, Arizona • Tempe, Arizona • Bryant, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Not applicable Interventional Results available

A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.

NCT02210208
View directory record Official record
Conditions
Burn Injury, Skin Graft
Interventions
Mepitel® Ag, Mepilex® Transfer Ag
Device
Lead sponsor
Molnlycke Health Care AB
Industry
Eligibility
18 Months to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Phoenix, Arizona • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder

NCT03835117
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Wide-spectrum nutritional supplement, Placebo
Drug · Other
Lead sponsor
Rossignol Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Recruiting No phase listed Observational

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

NCT06504589
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 28, 2026, 9:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Mosliciguat in PH-ILD

NCT06635850
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
Mosliciguat, Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

NCT04634604
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab, Laser
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Results available

Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants

NCT00859547
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
rThrombin, 1000 IU/mL
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 28, 2026, 9:42 PM EDT
Not listed Phase 1 Interventional

Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration

NCT00767949
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
iSONEP
Biological
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 28, 2026, 9:42 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence

NCT06862648
View directory record Official record
Conditions
Stress Urinary Incontinence (SUI)
Interventions
Acoustic Stimulation Therapy Device, Sham Acoustic Stimulation Therapy Device
Device
Lead sponsor
Acoustic Wave Cell Therapy, Inc.
Industry
Eligibility
22 Years to 77 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Phoenix, Arizona • Lakeland, Florida • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00290017
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary
Interventions
talabostat, pemetrexed
Drug
Lead sponsor
Point Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
101
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2007 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

NCT00118768
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, Pegylated Interferon Alfa
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Timeline
Started 2005
U.S. locations
19
States / cities
Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

NCT00931632
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Days to 14 Days
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02493452
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
191
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

NCT02049138
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13)
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 100 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
52
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 28, 2026, 9:42 PM EDT
Terminated Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

NCT00003378
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 80 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 28, 2026, 9:42 PM EDT
Active, not recruiting Phase 3 Interventional

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247
View directory record Official record
Conditions
Leukemia
Interventions
Quizartinib, Placebo, Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
52
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
109
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 28, 2026, 9:42 PM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

NCT02923778
View directory record Official record
Conditions
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Talimogene Laherparepvec
Procedure · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

NCT01616485
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
TA-1790, Sildenafil citrate, Placebo, Nitrostat
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

NCT01324232
View directory record Official record
Conditions
Central Neuropathic Pain, Multiple Sclerosis
Interventions
AVP-923-45, AVP-923-30, AVP-923-20, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 28, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

NCT04981704
View directory record Official record
Conditions
Healthy
Interventions
Poziotinib, Itraconazole, Phenytoin, Paroxetine
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 28, 2026, 9:42 PM EDT